reason report
bottom line recent wide thought amgen
mp aimovig erenumab teva fremanezumab would
first two cgrp target migrain medic receiv
regulatori approv expect year follow
fda warn letter teva januari impact activ
pharmaceut ingredi api product one celltrion
manufactur facil colleagu ami fadia subsequ
medacorp kol convers link expect teva market
entri delay offer upsid compani
lilli mp alder op launch
cgrp migrain prevent medicin advanc teva
like approv estim approxim million individu
suffer moderate-sever episod chronic migrain
take one sever calcitonin gene-rel peptid cgrp antibodi
within five year believ amgen aimovig erenumab
expect first launch retain greatest share among
differ biolog space increment posit
alder eptinezumab believ notabl beneficiari
teva delay due dose frequenc similar two drug
updat market model forecast teva alder medicin
approv within sever month erenumab
eptinezumab retain addit share long term given updat
base new competit assumpt updat
revenu earn forecast alder cgrp
antibodi increas sale estim
aimovig erenumab year boost
price target previous alder updat forecast
eptinezumab increas total revenu estim high singl
low doubl digit percentag year updat price target
alder previous maintain market
perform rate stock outperform rate alder
teva entri share gain aldr previous expect
teva launch respect antibodi around mid-
year year recent disclosur teva well colleagu
ami fadia due dilig suggest fremanezumab unlik
approv current june pdufa date given fda warn
letter fill/finish facil contract manufactur result
insight believ erenumab pois six
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
month lead-tim advantag nearest cgrp competitor
like lilli galcanezumab like approv
believ alder eptinezumab also beneficiari fremanezumab
delay given dose profil two antibodi suggest
either requir eptinezumab select fremanezumab in-offic
administr compar two subcutan cgrp antibodi
develop univers self-administ updat
market model forecast fremanezumab enter migrain prevent
market within month alder eptinezumab versu month
ahead previous believ result better adopt
competit posit alder drug
learn teva sec file one manufactur
facil respons api product receiv warn
letter januari year celltrion facil south korea
current sourc api fremanezumab sever teva
biolog product neither teva fda provid updat
regard approv fremanezumab current june review
date yet howev recent analysi colleagu ami fadia
suggest unlik fremanezumab approv current
pdufa date sinc mani specif issu identifi fda
warn letter take month longer address
concern issu letter pertain asept process
contamin believ make difficult regulatori
agenc overlook set approv new molecular entiti
particularli sinc issu broadli relat facil
oppos isol aspect product singl line
updat model delay launch time fremanezumab
begin
highlight prior note note clariti mani front succe
larg effect size efficaci profil eptinezumab appear demonstr rapid onset
symptom relief effect size high end potenti better
competitor believ greatest investor controversi regard eptinezumab adopt
indic mostli regard posit intraven later entri market
two three approv subcutan medicin similar overal benefit
erenumab lilli galcanezumab subcutan antibodi given monthli
teva fremanezumab subcutan week week inject eptinezumab iv
week inject expect teva commerci monthli
quarterli dose schedul fremanezumab order reach patient differenti
competitor appear fremanezumab third subcutan antibodi
launch potenti launch around time eptinezumab seem like
quarterli dose regimen may offer greatest opportun adopt suggest
fremanezumab eptinezumab compet similar cohort patient sever
migrain order achiev high enough dose week administr fremanezumab
must administ three subcutan inject time administr
make drug similar eptinezumab frequenc dose burden less
similar two subcutan antibodi lilli exhibit assum
least quarterli dose schedul mani patient like prefer visit
physician treatment administ rather self-administ three sc
exhibit dose profil cgrp antibodi
erenumabgalcanezumabfremanezumabeptinezumabrout monthli quarterlyquarterlyeas self administrationsourc compani present leerink research
model estim million individu suffer moderate-sever
episod chronic migrain unit state forecast total number
individu treat cgrp antibodi increas million
four market antibodi near peak penetr rate revis model
erenumab enter market around captur nearli entir cgrp market
share patient three competitor begin erod erenumab
share expand market subsequ year previous estim long-term
market share three subcutan antibodi erenumab fremanezumab
galcanezumab would similar updat model forecast erenumab galcanezumab
captur treat patient long term fremanezumab eptinezumab iv sc
account around estim rest world market approxim
commerci market us market share antibodi similar
us
erenumab aimovig forecast global risk-adjust sale million
peak risk-adjust sale billion use probability-of-success
increas prior estim million billion risk-adjust sale
year updat forecast substanti recent consensu estim earli year
recent consensu estim outer year increas aimovig forecast
result increas total revenu increas pro forma dilut ep
remain modestli recent consensu total revenu forecast
futur year revis earn forecast recent consensu
recent consensu price target increas
previous blend dcf price-to-earnings p/ basi
alder eptinezumab forecast global risk-adjust sale million first full
year launch million alder grow billion billion alder
global sale figur includ rest-of-world sale book larger pharmaceut partner
assum royalti rate alder assign probabl approv
eptinezumab commerci launch us begin second half addit
total sale estim made minor oper expens adjust
lengthen estim durat net oper loss nol off-set pre-tax incom
updat price target previous deriv via dcf methodolog
appli discount rate termin growth rate
rate aldr share outperform alder biopharmaceut late stage biotechnolog
compani guid develop lead product eptinezumab monoclon antibodi
seek prophylax migrain eptinezumab member larg emerg class
anti-cgrp anti-calcitonin gene relat peptid cgrp area heavi competit
mp partner nv mp teva mp aldr recent announc top-
line data promis phase studi chronic migrain consist first
phase studi episod migrain demonstr fast speed onset high proport
super respond across anti-cgrp group aldr compani develop
iv though expect patient prefer at-hom administr believ
defined/differenti market exist durabl in-offic infus physician
make money beyond iv formul eptinezumab aldr develop subcutan
formul test monthli quarterli dose
estim price target aldr month use dcf analysi
dcf valuat employ discount rate termin growth rate believ
discount rate reason consid clinic stage compani dcf
valuat includ net cash dilut secur addit forecast cash flow
believ eptinezumab grow time achiev global risk-adjust sale
includ royalti outsid us includ probability-of-success iv
self-administr peak market share anti-cgrp market
risk valuat includ fda/ema approv risk eptinezumab risk
clinic program delay competit risk given presenc multipl anti-cgrp
antibodi manufactur risk risk disappoint clinic data risk dilut
financ model addit equiti rais
price target inc stock rate market perform
one first gener pioneer biopharmaceut industri succeed
basi build three massiv revenu pillar legaci product era
enbrel face array brand gener competitor mean
associ revenu total like steadili declin offset outlook
number recent develop acquir product growth
profit potenti unlik match legaci brand least mani year amgen
manag respond challeng restructur compani expens base
initi dividend lever compani balanc sheet cash trap off-shore
gener make legaci product compar peer regard
defens stock also one lack explos upsid potenti typic associ
breakthrough rapidli grow biotherapeut stock
price target inc base averag three approach
believ reason basi valu stock today approach simpl
price earn multipl larg cap us eu larg cap biopharma stock azn
sni rhhbi gsk nv celg price sale multipl larg cap biotechnolog
pharma compani novo celg discount cash flow dcf use
rel multipl larg cap biopharma compani ep appli
ep estim give one year futur valu use establish
larg cap futur revenu multipl sale appli revenu forecast
give futur valu final dcf valuat base
current outlook compani exist product probability-weight revenu
contribut late stage pipelin program discount compani
wacc give fair valu today averag three approach give price
target
risk view outlook valuat includ major chang label
price reimburs coverag compani legaci product failur
compani growth portfolio achiev futur sale forecast risk includ develop
delay disappoint earlier stage pipelin asset earlier signific eros
compani legaci product biosimilar innov competit shortfal
compani effort improv oper margin would also materi affect outlook
valuat would larg dilut acquisit therapeut area platform
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
million
corp partner revenue incl royalti
po probabl success fda approv
leerink partner research compani file
million
sale incl kyproli
total expens exclud revenue sharing/incl sg
 total revenu
sg total revenu excl profit share
profit share total revenu
leerink partner research compani file
analysi stock price leerink target
method model larg cap healthcar growth stock ep multipl
ep appli amgen ep
leerink updat ep estim
current averag ep multipl consensu ep
compar slow grow us eu larg cap biopharma
impli target price ep
revenu multipl appli leerink revenu forecast
leerink updat revenu estim
current averag larg cap biopharma multipl revenu
impli valu fy revenu
impli target price ep use us pharma compar
method dcf adjust debt declin flow
stabl termin cash flow growth discount
present valu flow termin valu
averag method
leerink partner research compani file factset
ip royalti teva
licens clazakizumab
alder bs cf mm
chang
sec file leerink partner research
termin valu discount
